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Abstract 
            Background: Depressive and anxiety disorders are common among diabetic patients and 
are associated with high risk of diabetes- related complications and mortality. This study presents 
a meta-analysis of studies investigating depression and anxiety in diabetic patients.   
Aim: To conduct a meta-analysis in order to estimate the prevalence and odds ratio of 
clinically diagnosed depression and anxiety in individuals with diabetes mellitus (type 1 and 2) 
compared to those without. 
Methods: PubMed database was searched using MeSH terms to identify relevant studies 
that reported the prevalence of depression and /or anxiety in diabetes. Published reference lists of 
other meta-analyses on the subject were also examined. We used Event Rate (ER) to assess the 
prevalence rates and Odds Ratios (ORs) to assess the prevalence and likelihood (respectively) of 
depressive and anxiety disorders. Age and gender were checked as moderating factors. 
Results: In total, 16 studies met the inclusion criteria; 5 (30%) studies included a non-
diabetic control group. Prevalence rates for depression in diabetic patients based on 11 studies 
varied from 8.7% to 21.4%, while for anxiety disorders rates varied from 10.1% to 27.2 %. Older 
patients manifested higher rates of depression and anxiety. Less female diabetic patients 
manifested depression in comparison to men, while more female diabetics had anxiety in 
comparison to male patients. In controlled studies, the odds of depression in the diabetic group 
were 1.7 times that of the non-diabetic control group (OR= 1.722, (95% CI= 1.347 to 2.202, p< 
0.001), while the odds ratio of anxiety in diabetic patients were not significant. Also, in the 
controlled studies there was no significant correlation of age or gender with the prevalence of 
depression in the diabetic group.  
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Conclusions: Analyses demonstrate a moderate to high prevalence of depression and 
anxiety among diabetic patients.  Finally, diabetics have a higher risk to manifest depressive 
disorders in comparison to people without.   
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Introduction 
1.1 Diabetes Mellitus 
Diabetes Mellitus (DM), commonly referred to as diabetes, is a chronic, lifelong 
condition. Diabetes results from defects in insulin action, secretion or both (Alberti & Zimmet,, 
1998) meaning that the condition is due to the pancreas not producing the proper amount of 
insulin or the body cells not responding properly to the insulin produced (Shoback, , 2011). . 
Diabetes consists of a group of metabolic diseases characterized by hyperglycemia, a condition 
in which there are high blood sugar levels over a prolonged period of time (Herman, 2007). 
Common symptoms of marked hyperglycemia include weight loss, increased thirst (polydipsia) 
and hunger (polyphagia), and frequent urination (polyuria) (Cooke, Plotnick, 2008).  
Diabetes Mellitus is classified into two broad etiopathogenic categories; type 1 and type 
2.  Gestational diabetes is the third main form of diabetes, and it occurs in pregnant women with 
high blood sugar levels. Unlike diabetes 1 and 2, gestational diabetes is transient and may 
improve or disappear after delivery (Cash, 2014).  
Diabetes type 1 is characterized by a deficiency of insulin secretion, and results from the 
autoimmune destruction of the insulin-producing beta-cells in the pancreas (Rother, 2007). This 
type was formerly known as juvenile diabetes, as it is usually diagnosed in children and young 
adults. Administration of insulin therapy is essential, life-long and usually doesn’t impair normal 
daily activities and function. Diabetes type 1 affects between 5% and 10% of diabetic cases 
(American Diabetes Association, 2014). Diabetes type 2 is characterized by hyperglycemia and 
insulin resistance, which may be combined with inadequate compensatory insulin secretion 
(Shoback, 2011). Diabetes type 2 is the most prevalent form of diabetes, as it accounts for almost 
90% of diabetic cases (American Diabetes Association, 2014). Excessive body weight and 
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absence of physical exercise are the primary causes of this form of diabetes (Abdullah, Peeters,  
de Courten & Stoelwinder, 2010). This type is initially managed by exercise and diet and if 
blood sugar levels remain high, treatment with medication such as metformin or insulin may be 
used (Turner, Cull, Frighi, Holman, 2005).  
The chronic high blood sugar of diabetes is related with long-term damage, dysfunction 
and failure of various organs (Alberti & Zimmet,, 1998), commonly the kidneys, nerves, eyes, 
heart and blood vessels. Acute, life-threatening complications of uncontrolled or untreated 
diabetes include diabetic ketoacidosis and the nonketotic hyperosmolar syndrome (Kitabchi, 
Umpierrez, Miles, Fisher, 2009). 
Long-term complications of diabetes include nephropathy, often resulting in kidney 
failure; retinopathy with potential damage to the eyes or loss of vision; proximal diabetic 
neuropathy that causes weakness and painful muscle atrophy; peripheral neuropathy associated 
with diabetes-related foot problems, such as foot ulcers or Charcot joints with risk of amputation; 
autonomic neuropathy leading to cardiovascular and gastrointestinal complications (Alberti & 
Zimmet,, 1998). Also, diabetic patients are at greater risk for stroke, cardiovascular (Herman, 
2006; Sarwar et al., 2010) and cerebrovascular disease (Sarwar et al., 2010), and about 75% of 
deaths in diabetic patients are due to coronary artery disease (O'Gara et al., 2013).  
In 2013 the prevalence of diabetes was estimated at 382 million people worldwide, while 
according to the World Health Organization, diabetes was the 8
th
 leading cause of death in 2012, 
resulting in 1.5 million deaths. Diabetes mellitus occurs throughout the world, both in developed 
and developing countries, but remains uncommon in the underdeveloped world. Globally, the 
prevalence of diabetes is similar amongst women and men (Vos et al., 2014). Gale and Gillespie 
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in their article on Diabetes and Gender in 2001, note that it is often considered to be little bias 
related to gender or sex differences within Type 1 or Type 2 diabetes mellitus. Specifically, 
diabetes type 1 diabetes is considered to be the only major organ-specific autoimmune disorder 
not to be more prevalent in female populations (Gale & Gillespie, 2011). Type 2 is equally 
prevalent among male and female populations, while some evidence suggests slight male 
preponderance in middle age (Gale & Gillespie, 2001). With regard to age, Wild et al. (2004), 
report that in developed countries the majority of diabetics are >64 years of age, while in 
developing countries the majority of diabetic people is in the 45-65 year range.  
1.2 Depression and anxiety in diabetes mellitus 
Depression refers to a state of low mood and indisposition to activity that can influence 
one’s thoughts, behavior, emotions and sense of well-being (Diagnostic and Statistical Manual of 
Mental Disorders, fifth edition, American Psychiatric Association 2013).  Depressed mood can 
be a feature of major depressive disorder. Individuals with clinical depression can experience 
feelings of sadness, fatigue, guilt, worthlessness, lack of concentration, irritability, suicidality 
and changes in sleep, appetite and /or activity (Diagnostic and Statistical Manual of Mental 
Disorders, fifth edition, American Psychiatric Association 2013). Depressive mood disorder is a 
major cause of morbidity worldwide and as of 2010 affects approximately 4.3 % of the global 
population (Vos et al. 2012). Population studies have consistently demonstrated clinical 
depression to be twice as common in females than in males (Kuehner, 2003). 
Anxiety disorders constitute of a category of mental disorders characterized by feelings 
of fear and anxiety (Diagnostic and Statistical Manual of Mental Disorders, fifth edition, 
American Psychiatric Association 2013). Fear manifests as a reaction to current events, while 
anxiety is a worry concentrated on future events (Diagnostic and Statistical Manual of Mental 
7 
 
Disorders, fifth edition, American Psychiatric Association 2013). Common physical symptoms 
caused by these emotions are racing heart and shakiness (Diagnostic and Statistical Manual of 
Mental Disorders, fifth edition, American Psychiatric Association 2013). Among others, anxiety 
disorders include: generalized anxiety disorder, specific phobia, panic disorder, social anxiety 
disorder and post-traumatic stress disorder (Diagnostic and Statistical Manual of Mental 
Disorders, fifth edition, American Psychiatric Association 2013). Often, there is comorbidity of 
anxiety with other mental disorders, such as major depressive disorder and bipolar disorder. In 
2010, anxiety disorders affected approximately 4.5 % of the global population, and are more 
prevalent in women (5.2 %) than men (2.8 %) (Vos et al., 2012).  
There are studies suggesting that depression and diabetes are comorbid to a significant 
extent and that depressive disorders are associated with high risk of diabetes- related 
complications and mortality (Vanderlip, Katon, Russo, Lessler, & Ciechanowski, 2014). It has 
been reported that depression affects about 20% to 25% of diabetic patients, is common in both 
type 1 and type 2 diabetes, and has significant effects on the course and outcome of this medical 
condition (Ladea, Barbu, & Rosu, 2013).  Depressive disorders are a major factor causing 
hospital admissions among diabetic patients (Erkie, Feleke, Desalegne, Anbessie, & Shibre,  
2013) and out-patient attendances and emergency department presentations with diabetes-related 
difﬁculties (Garrett & Doherty, 2014) . 
            The interaction of depressive disorders and diabetes has been found to be synergistic, 
impairing overall functioning and quality of life. Depression has additional importance due to its 
association with poor outcomes in disease control (Joseph, Unnikrishnan, Babu,, Kotian, & 
Nelliyanil,  2013), poor metabolic control, low compliance with diabetes treatment and greater 
risk for micro- and macrovascular disease complications needs reference . In this case, metabolic 
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control refers to glycemic management (control of glucose levels) and disease control refers to 
the general management of the disease (i.e. self-care, exercise, adherence to diet, commitment to 
therapy, monitoring of glycemic levels).   
The prevalence of Generalized Anxiety Disorder (GAD) in diabetic patients is estimated 
up to 14%, while anxiety symptoms can influence up to 40% of the diabetic population (Grigsby, 
Anderson, Freedland, Clouse, & Lustman, 2002). Anxiety disorders, like depressive disorders 
are associated with poor adherence to treatment as well as inadequate glycemic control (Collins, 
Corcoran, & Perry, 2009).  
Recent studies indicate that elevated glucose levels can influence the development of 
anxiety and depressive disorders (Wang, Tsai, Chou, & Chen, 2008). On the other hand, there is 
evidence that depression is a risk factor for the development of diabetes (Mezuk, Eaton, 
Albrecht, & Golden, 2008). These findings may suggest that there is a bidirectional association 
between the existence of diabetes and the occurrence of depressive disorders, although few 
studies have assessed or reviewed this hypothesis.  
             There are several meta-analyses that describe the relationship between diabetes and 
depression. In 2001, Anderson et al. found that the prevalence of comorbid depression was 28% 
in diabetic women and 18% in diabetic men.  Another meta-analysis by Ali, Stones, Peters, 
Davies and Khunti in 2006 showed similar results with depression rates significantly higher in 
diabetic women than in diabetic men (23,8% and 12,8% respectively). Anderson et al. highlight 
that the prevalence of comorbid depression was notably higher in uncontrolled studies (30%) 
than in controlled studies (21%). A systematic review by Barrnard, Skinner and Peveler (2006) 
indicates that the incidence of clinical depression in controlled studies was 12% and in studies 
with no control group the prevalence of clinical depression was 13.4%.  
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 Evidence based on systematic reviews on this topic indicate that depression is a 
substantial risk factor for diabetes (Mezuk et al., 2008) and that depressive disorders are 
associated with increased risk of mortality in diabetic patients (Park, Katon, Wolf, 2013; Van 
Dooren, Nefs, Schram, Vehrhey, Denollet, Pouwer, 2013) . There are fewer meta-analyses and 
articles researching the interaction between anxiety disorders and diabetes compared to those 
investigating the relationship between depression and diabetes.  
              It is documented that approximately one third of people with diabetes face 
psychological and/or social issues which interfere with their ability to self- manage their disease 
(Garrett & Doherty, 2014).This suggests that it is important for more studies to be carried out in 
order to examine in further detail the proportion and the components associated with the 
prevalence of depressive and anxiety disorders amongst people with diabetes  
1.4 Aim of the study 
The primary objective of this study is to investigate the prevalence of clinically 
diagnosed depression and anxiety disorders among patients with diabetes mellitus (type 1 and 2) 
using a meta-analysis. A secondary aim of this report is to examine the role of age and gender in 
relation to depression and anxiety in the diabetic population. Scientific research has found 
depression and anxiety to be more prevalent in women than in men (Kuehner, 2003; Vos et al., 
2012). Moreover, diabetes mellitus is considered to be an age-prevalent disease, with increased 
chances of diagnosis as one ages (Gambert & Pinkstaff, 2006). Therefore, this study evolves 
around the following research questions: a) What is the prevalence of depression and anxiety 
disorders in diabetic people? b) Are there differences in the prevalence of depression and anxiety 
disorders in diabetic patients compared to healthy controls? c) Are there effects of age and 
gender in the context of the comorbidity of diabetes and the aforementioned mental disorders?  
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Methods 
2.1 Online search strategy and information sources 
A systematic electronic research was conducted from December 2014 until January 2015 
using the PubMed online search engine, in order to identify and scrutinize studies that 
investigated the comorbidity of depression and anxiety disorders with diabetes. The terms 
entered in the search engine were the following: (“diabetes”) AND (“depression” OR 
“depressive disorder”) and in a separate search, (“diabetes”) AND (“anxiety” OR “anxiety 
disorder”).  
The initial search showed 10,492 articles that were screened based on their titles and 
abstracts, while papers that didn’t provide enough information in the abstract were read in full 
form.  
Inclusion criteria were: a reported diagnosis of diabetes and diagnosis of 
depressive/anxiety disorders by a clinician. In addition the article should report the necessary 
data and all the results should be published in a peer reviewed journal. 
Studies were excluded when data is reported in meta-analyses, when the studies report 
self-rated depressive/anxiety symptoms, when studies are performed on non-human subjects and 
finally when studies are not written in English, French, Spanish or Greek, German, Dutch or 
Italian. 
            Data collection 
The data extracted for the writing of this meta-analysis include information on authors, 
year of publication, journal of publication, country that the study took place, study design, setting 
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of the research (i.e. hospital, institution, home doctors), diagnosis of diabetes and diagnosis of 
depression and/or anxiety (based on clinical interview). Other information included refer to the 
number of participants (cases/controls) or number of patients (in larger population-based 
studies), specific characteristics of the population in research (age, gender) and  follow-up 
information, if such information was available. 
2.2 Study selection 
In the end of the first screening, studies were eligible when i) structured clinical 
interviews were used for the psychological assessment of depression and/or anxiety ii)  
depression or anxiety diagnosis was based on ICD (World Health Organization, 2014) diagnostic 
codes c) prevalence rates of depression and/or anxiety in patients with diabetes were reported iii) 
prevalence rates of diabetes in patients with depression and/or anxiety were reported iv) 
prevalence rates of depression and/or anxiety of diabetic samples were directly compared to 
those of healthy control groups v) cohort studies registered the incidence of depression/and or 
anxiety and diabetes.  
The structured clinical interviews used for the assessment and diagnosis of depression 
and anxiety are the following: Composite International Diagnostic Interview (CIDI) (Robins et 
al., 1988), Structured Clinical Interview (SCID) (Spitzer, Williams, Gibbon, First, 1992), 
Diagnostic Interview Schedule (DIS) (Robins,  Helzer, Croughan,  Ratcliff, 1981), Mini 
International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) and the Computerized 
Diagnostic Interview Schedule (C-DIS) (Blouin, Perez, Blouin, 1988). 
The International Classification of Diseases (ICD) is developed as a health care 
classification system in order to provide a system of diagnostic codes for the classification of 
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diseases (World Health Organization, 2014). The ICD is published by the World Health 
Organization (WHO) and is used globally for mortality and morbidity statistics and 
epidemiology, as well as in reimbursement systems and in automated decision support in health 
care. In the case of mental and behavioral disorders, the ICD code system is based on the 
Diagnostic and Statistical Manual of mental disorders (DSM) and is used to provide diagnostic 
assistance and statistically classify mental health disorders (World Health Organization, 2014). 
2.2 Data Extraction 
From the initial overview of the PubMed online results (10,492 articles) we concluded in 
32 possibly relevant articles, of which 16 were found eligible for this study. A data extraction 
worksheet was developed and used to gather information on the author’s data; year of 
publication; country and setting where the study took place; sample sizes; method of psychiatric 
assessment or diagnosis of diabetes; adjusted and/or unadjusted odds ratios and confidence 
intervals (if applicable); prevalence of depression and/or anxiety in diabetic samples.  
Data on the demographic characteristics of the diabetic samples were extracted as well, 
including the mean/median age and the percentage of female subjects in a particular study. When 
the mean age was not given but data on the age were presented in age bands, the median age was 
calculated using the age band with the larger amount of participants. 
2.3 Statistics 
The statistical analyses were performed using the Comprehensive Meta-Analyses 
program (CMA), version 2 (Borenstein, Hedges, Higgings & Rothstein, 2009). Random-effects 
models were applied in order to calculate i) the effect sizes of the prevalence of depression 
and/or anxiety between diabetic samples and healthy control groups ii) the point estimates of the 
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prevalence of the aforementioned psychiatric disorders in the diabetic samples. For the studies 
that provided data solely on diabetic samples, the prevalence of depression and anxiety was 
computed using the event-rates (ER), centered at 0.00 with 95% confidence intervals, while for 
the studies that provided data on diabetic samples and healthy controls, the comparison of 
prevalence of depression and anxiety between those groups was computed using the Odds-Ratio 
(OR), centered at 1.00 with 95% confidence intervals. Furthermore, meta-regression analyses 
were performed to illustrate possible effect of age and/or gender on the strength of the 
association between diabetes and depression and/or anxiety. 
The variation in study outcomes between studies was measured by Cochran’s Q statistic 
value with 95% Confidence Interval CI, and the extent of heterogeneity was calculated by the I² 
statistic value, which illustrates the proportion of variation that is due to heterogeneity across the 
studies rather than chance (Higgins and Thompson, 2002; Higgins et al., 2003).To check for 
possible publication bias the Egger’s regression test was computed. Publication bias was also 
illustrated through funnel plots. 
3. Results 
3.1 Description of the sample 
Overall, 16 studies met the criteria set for this meta-analysis. Sample sizes and 
demographic characteristics of the samples are summarized in Table 1. The sample size of the 
studies included ranged from N= 46 to N= 782020.  In 9 out of 16 studies the percentage of 
females was larger than that of the males, in 4 studies there were more male participants and in 
another 3 studies men and women were equally represented in the sample.  In total, 4 studies 
provided incomplete or missing data on the mean age and/or female percentage. The study of 
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Dowden et al. didn’t provide information on the mean age and female percentage of the sample. 
Also, information on gender distribution was not applicable for the study of Pibernik-Okanovic 
et al. (2004) and of Mayou et al. (1991). Data on the mean age of the sample was missing from 
the study of Egede (2004). 
Furthermore, 11 studies examined the association of diabetes with depression, 1 study 
focused on anxiety in diabetic patients, while 7 studies reported data on both depressive and 
anxiety disorders in diabetic samples. The majority of the studies (7 studies) were conducted in 
Europe (France, Sweden, Finland, Poland, Spain, Croatia and Great Britain) and in USA (6 
studies). Of the remaining studies, one was conducted in Taiwan, one in India and one in 
Australia.  
 
Author, Year of publication Sample size (N) Age (n) Female percentage  
(%) 
 Depression 
 
  
Wandell et al. 2014 a 96103 50, median 43 
Lynch et al. 2014 625903 64, mean 2 
Alonso-Moran et al. 2014 126894 65, median 74.2 
Ali et al. 2013 122 47.2, mean 50.8 
Lin et al. 2012 782020 57, median 50 
Dowden et al. 2011 
Kokoszka et al. 2009 
Pibernic-Okanovic et al. 2005 
Thomas et al. 2003 a 
Nichols & Brown 2003 
Cohen et al. 1997 a 
Mont-Marin et al. 1995 a 
Kokkonen at  al. 1995 a.  
Mayou et al. 1991 a 
Wells et al. 1989 a 
Lustman et al. 1986 a 
1592 
101 
384 
104 
16190 
49 
46 
63 
109 
154 
114 
 
 
Anxiety 
* 
64, mean 
57, mean 
50.6, mean 
61, mean 
36.3, mean 
51, mean 
20.9, mean 
21.9, mean 
39.5, mean 
40, mean 
* 
60 
* 
73.1 
63 
62 
63 
41.3 
* 
50.4 
67 
Wandell et al. 2014 b 96103 50, mean 43 
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Huang et al. 2011 
Thomas et al. 2003 b 
Cohen at al. 1997 b 
Mont-Marin et al. 1995 b 
Kokkonen at al. b 
Mayou et al. 1991 b 
Wells et al. b 
Lustman et al. 1986 b 
5685 
104 
49 
46 
63 
109 
154 
93 
59, median 
50.6, mean 
35.6, mean  
51, mean 
20.9, mean  
21.9, mean  
39.5, mean 
40, mean  
 
52 
73.1 
57 
63 
41.3 
* 
50.4 
67 
    
    
    
    
Table 1. Sample sizes of diabetic patients and demographics. 
3.2 Prevalence of depression and/or anxiety in diabetic patients. 
The prevalence of depressive disorders in diabetic samples based on 11 studies (N= 
1633294) varied from 8.7% to 21.4% (see Figure 1.). Prevalence rates for anxiety disorders 
among diabetics based on data from 6 studies (N= 102085) varied from 10.1% to 27.2 % (see 
Figure 2.). The overall estimate of depressive disorders in diabetic samples is 13. 9 % while for 
anxiety disorders is 17.0  %. .  
 
 
Figure 1. Prevalence rates of depression in diabetic samples.  
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Figure 2. Prevalence rates of anxiety in diabetic samples. 
 
Meta regression analyses 
Analyses illustrate a significant association of age and gender with the prevalence of 
depression in diabetic patients (p = <0.001). There was a positive correlation between age and 
depressive disorders in diabetic patients, as older patients had higher depression prevalence 
(slope = 0.099, 95% CI = 0.908 to 0.100, p = < 0.001) (see Figure 3). On the other hand, gender 
was negatively associated with depression (slope = -0.015, 95% CI = - 0.016 to - 0.015, p = < 
0.001), as less female diabetic patients manifested depressive disorders in comparison to men.   
 
Figure 3. Regression of Age in diabetics with comorbid depression. 
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.  
Figure 4. Regression of female percentage in diabetics with comorbid depression. 
 
 Age was positively associated with the prevalence of anxiety disorders since older 
patients had higher anxiety rates (slope = 0.064, 95% CI = 0.055 to 0.072, p = < 0.001). Gender 
was also positively correlated with anxiety (slope = 0.098, 95% CI = 0.090 to 0.106, p = <0.001), 
as more female diabetics manifested anxiety disorders compared to male patients. Finally, both 
age and gender were significantly associated with anxiety disorders (p = < 0.001).  
 
Figure 5. Regression of Age in diabetics with comorbid anxiety. 
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Figure 6. Regression of Female percentage in diabetics with comorbid anxiety. 
 
A high degree of heterogeneity was observed across the core analyses for depressive (Q = 
43899.662, df (Q) = 10, p = <0.001, I
2
 = 99.977) and anxiety disorders ( Q = 621.710, df (Q) = 5, 
p = <0.001, I
2 = 99.196). Moreover, according to Egger’s test for depressive (t = 0.31958, p = 
0.75658) and anxiety disorders (t =1.86714, p = 0.13528) publication bias was not significant for 
these studies; for funnel plots see Figure 7,8.  
 
Figure 7. Funnel plot for studies reporting data on depression.  
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Figure 8. Funnel plot for studies reporting data on anxiety. 
3.3 Prevalence of depression and/or anxiety between diabetic samples and healthy 
control groups. 
To estimate the association of depressive and/or anxiety disorders in diabetics compared 
with healthy controls, a pooled random effects meta-analysis was conducted using data from 5 
studies, which examined the cross-sectional association between depression and/or anxiety in 
diabetics compared with those without diabetes.  This analysis included data for 16623 patients 
with diabetes and 3313 individuals without diabetes.  
The odds ratio for depression was significantly increased in patients with diabetes 
compared to those without. The overall effect size was OR= 1.722 (95% CI= 1.347 to 2.202, p< 
0.001), meaning that diabetic patients were 1.7 times more likely to manifest depressive 
disorders than people without diabetes.  
In contrast, the odds ratio for anxiety in diabetic patients was not significant (p = 0.68) 
with overall effect OR=0.693 (95% CI= 0.122 to 3.954).  
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Figure 9. Forest plot and effect sizes for random meta-analysis on the prevalence of depression in diabetic samples 
compared to healthy controls.  
 
Figure 10. Forest plot and effect sizes for random meta-analysis on the prevalence of anxiety in diabetic samples 
compared to healthy controls. 
Meta regression analyses 
To detect possible effect of age and gender in diabetic patients with co-morbid depressive 
or anxiety disorders, meta-regression analyses were conducted. There was a negative correlation 
of age with depressive disorders (slope = -0.007, 95% CI = -0.022 to 0.008, p = 0.359), as older 
diabetic patients reported lower rates of depression. Female percentage was also negatively 
associated with the prevalence of depression in diabetic samples (slope = -0.019. 95% CI = -
0.044 to 0.006, p = 0.134), as less female diabetics manifested depressive disorders compared to 
male patients. The effect of gender and age was not significant.  
Like depressive disorders, anxiety disorders were negatively and non-significantly 
associated with age. Specifically, older patients with diabetes reported lower rates of anxiety 
(slope = -0.037, 95% CI = -0.103 to 0.028, p = 0.268). In contrast, anxiety was significantly and 
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negatively associated with gender. Less female diabetics manifested anxiety disorders in 
comparison to men (slope  = -0.063, 95% CI = -0.105 to -0.021, p = 0.002).  
Heterogeneity and Publication bias 
For the studies reporting data on depressive disorders (Q = 5.518, df (Q) = 4, p= <0.238, 
I
2 
= 27.513) heterogeneity was not substantial or significant (as observed in funnel plot figure 
11). For articles reporting data on anxiety disorders heterogeneity was substantial and significant 
(Q = 21.093, df (Q) = 2, p= <0.001, I
2 
= 90.518). Furthermore, Egger’s test was run only for 
studies providing information on depression (t = 0.64106, p = 0.56710). The test could not be run 
for studies on anxiety, as there were only 3 articles on anxiety and there needs to be a larger 
amount of trials/strata in the meta-analysis for the bias assessment functions to work (see figure 
11). 
 
Figure 11. Funnel plot for studies reporting data on depression. 
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 4. Discussion 
4.1 Prevalence rates and Odds Ratios 
The primary aim of the study was to investigate the prevalence of clinically diagnosed 
depression and anxiety amongst patients with diabetes mellitus (type 1 and type 2).  For this 
purpose, there was sufficient data provided by the selected studies. Analyses demonstrate an 
aggregated prevalence rate of depression of 13.9 % among diabetic patients, which illustrates a 
modest to strong association between depression and diabetes mellitus.  The prevalence rates of 
depression (13.9 %) in diabetic patients were higher than the depression rates reported for the 
global population in 2010, which was 4.5 % (Vos et al., 2012).  
We found fewer studies that showed the prevalence of anxiety disorders in diabetic 
samples, compared to those showing the prevalence of depression. Analyses indicate an 
aggregated prevalence of anxiety disorders of 17 %  in diabetic patients, higher than the 
prevalence of anxiety disorders in the general population, which was approximately 4.5 %  in 
2010 (Vos et al. 2012).   
The second objective of this meta-analysis was to estimate the odds ratio of depressive 
and anxiety disorders in individuals with diabetes compared to those without. Based on data 
from 5 studies, depressive disorders were found to be 1.7 times more likely in diabetics than in 
healthy populations. Previous meta-analyses present similar findings. Specifically, Anderson et 
al. (2001), who included 20 studies in their meta-analysis, report that the odds of depressive 
disorders in the diabetic population was twice that of the comparison group (OR = 2.0, 95% CI 
1.8–2.2). Moreover, according to Ali et al. (2006), who included 10 studies, the prevalence rates 
of depression were significantly higher in comparison with the non-diabetic controls (17.6 vs. 
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9.8%, OR = 1.6, 95%, (CI) 1.2–2.0). Mezuk et al. (2008) describe in their meta-analysis (13 
studies) that there is a 60 % increased risk of type 2 diabetes in depressive disorder, while the 
latter is moderately associated with increased risk of depression.  Finally, Nouwen et al. (2010) 
in their meta-analysis (11 studies) illustrate that compared with non-diabetic control groups, 
individuals with diabetes type 2 have increased risk of 24 % of developing depression.  
Unlike depression, there was no significant increased risk of anxiety disorders in diabetic 
patients compared to control groups, probably due to the very small number of studies (only 3 in 
total).  
4.2 Age and Gender 
According to our findings, age was positively correlated with depression and anxiety 
based on the ER analyses assessing the prevalence of the aforementioned mental illnesses with 
diabetes mellitus. This suggests that older patients had higher rates of depressive and anxiety 
disorders.  
Our findings illustrate higher rates of depression in older diabetic patients and are in 
contrast with prior research, which suggests decline in depression and anxiety prevalence with 
age. Studies support that depression is more common in younger age both in diabetic samples 
(Katon et al., 2004) and healthy population samples(Gottfries, 1998) and that elderly people 
report less depressed mood (Gottfries, 1998).  
Regarding the effect of gender on the association of diabetes with depressive and anxiety 
disorders, ER meta-regression analyses show a significant correlation of gender with both 
depressive and anxiety disorders. According to our findings, depression was more prevalent in 
male diabetic patients than in female ones. This outcome is not consistent with prior meta-
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analyses on the comorbidity of diabetes with depression and anxiety. According to the meta-
analyses of Ali et al. (2006) and of Anderson et al. (2001), the prevalence of comorbid 
depression was significantly higher in female diabetic patients in comparison to men.  
Regarding anxiety disorders, our ER analyses present higher rates of anxiety in females 
compared to males. There are similar results in prior research supporting that anxiety disorders 
are more common in women (5.2 %) than in men (2.8 %) (Vos et al., 2012). Specifically, female 
diabetics are more likely to report moderate-severe anxiety compared to male patients (Lloyd et 
al. 2000; Grisby et al. 2002). In contrast, the OR meta-regression analyses investigating gender 
as moderator in relation to anxiety in diabetic patients demonstrate that less women with diabetes 
manifested anxiety disorders. This inconsistency with previous results could be attributed to the 
small amount of studies included in the analyses. 
4.3 Publication bias and Heterogeneity 
Egger’s test suggested no evidence of publication bias for the studies reporting 
prevalence data on depressive and anxiety disorders in diabetic samples. A high degree of 
heterogeneity was observed across these studies, meaning there was significant variation in 
outcomes between studies. The significant heterogeneity compromises the consistency of the 
results and the combinability of the studies.  
On the other hand, it worthy to note that there was no publication bias observed regarding 
the studies that reported data on depression in diabetic groups compared with controls. 
Moreover, there was no substantial heterogeneity observed across these studies.  
4.4 Strengths and limitations 
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There are various strengths and limitations observed in the present meta-analysis. Firstly, 
only studies using diagnostic interviews were included in the final analyses. Previous meta-
analyses and systematic reviews included also studies that used questionnaires as a diagnostic 
tool for depression. Psychiatric interviews consist of a more thorough mental examination 
compared to questionnaires. Furthermore, having one method of psychiatric assessment 
contributes to the homogeneity of the sample. 
Nonetheless, there are various limitations to this meta-analysis. In this meta-analysis type 
1 and type 2 diabetes are not distinguished, as most of the studies didn’t refer to the two types 
separately, but generally as ‘diabetes’. The publication bias displayed for studies reporting data 
on depressive and anxiety disorders is significant and compromises the validity and accuracy of 
the results describing the prevalence of depression and anxiety in diabetic patients.  The presence 
of publication bias could be attributed to the small number of studies, small sample sizes and 
small effect sizes. Also, the small amount of studies limits our ability to generalize the outcomes 
and take the main confounding variables into account. Moreover¸ there was heterogeneity 
illustrated across these studies as well, indicating a significant variation among the studies. This 
variation could be due to the difference in the design of the studies, which included retrospective 
cohort studies, prospective, and cross-sectional.  
Apart from the variation in study outcomes between studies, there was variation of the 
diabetic sample across the studies. For example, women and men were represented in different 
numbers in each study, some studies didn’t provide information on age or gender, age categories 
were defined differently in each study and some studies focused just on younger or older 
patients. In addition, some studies examined inpatients while other outpatients. Finally, the 
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studies differ in the diagnostic methods of diabetes, as some rely on diagnostic codes (ICD) and 
medical records, other on diagnosis by a physician and other on self-reports.  
4.5 Conclusions 
Although this meta-analysis aimed to describe an overall estimate of the prevalence of 
depression and anxiety in diabetic populations but also compared to healthy groups, a number of 
factors must be taken under consideration regarding the accuracy of this estimate.  The 
publication bias detected jeopardizes the accuracy and validity of the findings on the prevalence 
of depressive and anxiety disorders in diabetic patients. Also, valid conclusions on the 
prevalence of this comorbidity cannot be made due to substantial heterogeneity.  
Findings on the prevalence of depression in diabetics compared with healthy controls, 
indicates that diabetic patients are 1.7 times more likely to manifest depression than healthy 
individuals. These findings are in line with previous research. Our findings with regard to 
anxiety in diabetic individuals compared with healthy ones did not show an increased risk of 
anxiety disorders, and age and gender did not have a moderating effect. 
4.6 Suggestions for further research 
There is substantial need for high-quality research in order to direct a precise assessment 
of the unique association of diabetes mellitus and depressive as well as anxiety disorders. 
Research should include large population-based cohort studies, using diagnostic interviews for 
the assessment of mental disorders and appropriately matched control groups. Additionally, it is 
vital that type 1 and type 2 diabetes are distinguished and reported separately. Also, for a better 
illustration of the relationship of diabetes and depression or anxiety, there should be adequate 
data on moderating variables, such as age and gender. 
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